Literature DB >> 23248243

Donor lymphocyte infusion induces polyspecific CD8(+) T-cell responses with concurrent molecular remission in acute myeloid leukemia with NPM1 mutation.

Susanne Hofmann1, Marlies Götz, Vanessa Schneider, Philippe Guillaume, Donald Bunjes, Hartmut Döhner, Markus Wiesneth, Jochen Greiner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23248243     DOI： 10.1200/JCO.2011.41.1116

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  14 in total

Review 1.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 2.  Minimal residual disease in acute myeloid leukemia--current status and future perspectives.

Authors:  Sabine Kayser; Roland B Walter; Wendy Stock; Richard F Schlenk
Journal:  Curr Hematol Malig Rep       Date:  2015-06       Impact factor: 3.952

3.  Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy.

Authors:  V Schneider; L Zhang; L Bullinger; M Rojewski; S Hofmann; M Wiesneth; H Schrezenmeier; M Götz; U Botzenhardt; T F E Barth; K Döhner; H Döhner; J Greiner
Journal:  Leukemia       Date:  2014-03-28       Impact factor: 11.528

Review 4.  T cell optimization for graft-versus-leukemia responses.

Authors:  Melinda A Biernacki; Vipul S Sheth; Marie Bleakley
Journal:  JCI Insight       Date:  2020-05-07

Review 5.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

6.  Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.

Authors:  Jochen Greiner; Susanne Hofmann; Michael Schmitt; Marlies Götz; Markus Wiesneth; Hubert Schrezenmeier; Donald Bunjes; Hartmut Döhner; Lars Bullinger
Journal:  Haematologica       Date:  2017-09-21       Impact factor: 9.941

Review 7.  Clinical implications of molecular markers in acute myeloid leukemia.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Eur J Haematol       Date:  2018-10-23       Impact factor: 2.997

8.  Indoleamine 2,3-dioxygenase 1 (IDO1) activity in leukemia blasts correlates with poor outcome in childhood acute myeloid leukemia.

Authors:  Valentina Folgiero; Bianca M Goffredo; Perla Filippini; Riccardo Masetti; Giuseppina Bonanno; Roberta Caruso; Valentina Bertaina; Angela Mastronuzzi; Stefania Gaspari; Marco Zecca; Giovanni F Torelli; Anna M Testi; Andrea Pession; Franco Locatelli; Sergio Rutella
Journal:  Oncotarget       Date:  2014-04-30

9.  Pretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.

Authors:  S Kayser; A Benner; C Thiede; U Martens; J Huber; P Stadtherr; J W G Janssen; C Röllig; M J Uppenkamp; T Bochtler; U Hegenbart; G Ehninger; A D Ho; P Dreger; A Krämer
Journal:  Blood Cancer J       Date:  2016-07-29       Impact factor: 11.037

Review 10.  Immunological and Clinical Impact of Manipulated and Unmanipulated DLI after Allogeneic Stem Cell Transplantation of AML Patients.

Authors:  Jochen Greiner; Marlies Götz; Donald Bunjes; Susanne Hofmann; Verena Wais
Journal:  J Clin Med       Date:  2019-12-23       Impact factor: 4.241
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.